Upregulation of CD146 in Pediatric B-Cell Acute Lymphocytic Leukemia and Its Implications on Treatment Outcomes
Table 2
Immune features of B-ALL patients and their controls with significance.
Group
Mean
SD
SE
value
cd146.cd4
Patients
31
7.5853
3.517
.632
0.001
Controls
27
2.0168
.376
.072
cd146.cd8
Patients
31
8.392
3.798
.682
0.005
Controls
27
2.1782
.406
.0782
WBC
Patients
31
32.43
23.618
4.242
NA
Controls
NA
NA
NA
NA
HG
Patients
31
7.7677
1.749
.31430
NA
Controls
NA
NA
NA
NA
PLT
Patients
31
100.94
103.66
18.617
NA
Controls
NA
NA
NA
NA
BM blast%
Patients
31
59.0323
21.97
3.94655
NA
Controls
NA
NA
NA
NA
PB blast%
Patients
31
20.0839
9.84
1.76618
NA
Controls
NA
NA
NA
NA
CD34
Patients
31
52.3613
21.523
3.865
NA
Controls
NA
NA
NA
NA
CD146.blast
Patients
31
51.3472
24.133
4.334
NA
Controls
NA
NA
NA
NA
CD8
Patients
31
10.3497
5.409
.9715
NA
Controls
28
19.7607
10.509
1.986
Lymphocytes
Patients
31
34.9600
8.88
1.594
0.005
Controls
28
61.3578
12.21
2.306
CD4
Patients
31
23.1857
4.856
.872
0.003
Controls
28
39.8459
9.564
1.807
NA: not applicable; BM: bone marrow; PB: peripheral blast. Data were expressed as number, mean, SD, SE, and independent sample -test used for significance.
